Skip to main content
SpringerLink
Log in

Heparin Therapy: Regimens and Management

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neutralisation of thrombin and other activated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unless there exist compelling contraindications. Continuous intravenous infusion of heparin appears to be safer than intermittent injection.

Low-dose subcutaneous heparin is effective in preventing the initial occurrence of thigh vein thrombi and in reducing the incidence of fatal pulmonary embolism in general surgical patients over the age of 40. The efficacy of low-dose heparin in preventing pulmonary emboli following hip surgery has not been established.

The incidence of severe heparin-induced thrombocytopenia appears to be rising. Platelet counts should be performed in all patients receiving heparin by any mode of administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Babcock, R.B; Dumper, C.W. and Scharfman, W.B.: Heparin-induced thrombocytopenia. New England Journal of Medicine 295: 237–241 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Barritt, D.W. and Jordan, S.C.: Anticoagulant Drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1: 1309–1312 (1960)

    CAS  Google Scholar 

  • Bell, W.; Tomasulo, P.A.; Alving, B.M. and Duffy, T.P. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Annals of Internal Medicine 85: 155–160 (1976)

    PubMed  CAS  Google Scholar 

  • Brinkhous, K.; Smith, H.P.; Warner, E.D. and Seegers, W.H.: The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. American Journal of Physiology 125: 683 (1939)

    CAS  Google Scholar 

  • Deykin, D.: Thrombogenesis. New England Journal of Medicine 276: 622–628 (1967)

    Article  PubMed  CAS  Google Scholar 

  • Deykin, D. and Hellerstein, L.J.: The assessment of drug-dependent and isoimmune antiplatelet antibodies by the use of platelet aggregometry. Journal of Clinical Investigation 51: 3142–3153 (1972)

    Article  PubMed  CAS  Google Scholar 

  • Gallus, A.S. and Hirsh, J.: Prevention of venous thromboembolism. Seminars in Thrombosis and Hemostasis 2: 232–290 (1976a) See also Gallus, A.S. and Hirsh, J.: Antithrombotic Drugs. Drugs 12: 41–68 (1976)

    PubMed  CAS  Google Scholar 

  • Gallus, A.S. and Hirsh, J.: Treatment of venous thromboembolic disease. Seminars in Thrombosis and Hemostasis 2: 291–331 (1976b) See also Gallus, A.S. and Hirsh, J.: Antithrombotic drugs. Drugs 12: 41–68 (1976)

    PubMed  CAS  Google Scholar 

  • Harris, W.H.: Low-dose heparin in total-hip replacement. Lancet 2: 423 (1976)

    Article  Google Scholar 

  • International Multicentre Trial: Prevention of fatal post-operative pulmonary embolism by low doses of heparin. Lancet 2: 45–51 (1975)

    Google Scholar 

  • Karpatkin, S. and Siskind, G.W.: In vitro detection of platelet antibody in patients with idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Blood 33: 795–812 (1969)

    PubMed  CAS  Google Scholar 

  • Rosenberg, R.D.: Actions and interactions of heparin. New England Jurnal of Medicine. 292: 146–151 (1975)

    Article  CAS  Google Scholar 

  • Rosenberg, R.D. and Damus, P.S.: The purification and mechanism of action of human Antithrombin — heparin co-factor. Journal of Biological Chemistry 248: 6490–6505 (1973)

    PubMed  CAS  Google Scholar 

  • Sagar, S.; Stamatakis, J.D.; Higgins, A.F.; Nairn, D.; Maffei, F.H.; Thomas, D.P. and Kakkar, V.V.: Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet 1: 1151–1154 (1976)

    Article  PubMed  CAS  Google Scholar 

  • Salzman, E.W.; Deykin, D.; Shapiro, R.M. and Rosenberg, R.: Management of heparin therapy. Controlled prospective trial. New England Journal of Medicine 292: 1046–1050 (1975)

    CAS  Google Scholar 

  • Sevitt, S.: Venous thrombosis in injured patients (with some observations on pathogenesis); in Sherry, Brinkhous, Genton and Stengle (Eds) Thrombosis, p.29–49 (National Academy of Sciences, Washington DC 1969)

    Google Scholar 

  • Yin, E.T.; Wessler, S. and Stoll, P.J.: Biological properties of the naturally occurring plasma inhibitor to activated factor X. Journal of Biological Chemistry 246: 3703–3711 (1971)

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boston Veterans Administration Hospital, 150 South Huntington Avenue, Boston, Massachusetts, 02130, USA

    Daniel Deykin

Authors
  1. Daniel Deykin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deykin, D. Heparin Therapy: Regimens and Management. Drugs 13, 46–51 (1977). https://doi.org/10.2165/00003495-197713010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-197713010-00005

Keywords

Search

Navigation